Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$0.26 - $0.42 $25,223 - $40,745
-97,013 Reduced 18.74%
420,633 $109,000
Q4 2023

Feb 13, 2024

BUY
$0.26 - $0.8 $42,045 - $129,370
161,713 Added 45.43%
517,646 $153,000
Q3 2023

Nov 14, 2023

SELL
$0.58 - $0.86 $6,669 - $9,890
-11,500 Reduced 3.13%
355,933 $217,000
Q2 2023

Aug 11, 2023

BUY
$0.7 - $0.96 $18,830 - $25,824
26,900 Added 7.9%
367,433 $290,000
Q1 2023

May 12, 2023

BUY
$0.76 - $1.69 $7,448 - $16,562
9,800 Added 2.96%
340,533 $327,000
Q4 2022

Feb 13, 2023

SELL
$0.66 - $27.41 $14,124 - $586,574
-21,400 Reduced 6.08%
330,733 $218,000
Q3 2022

Nov 14, 2022

SELL
$0.62 - $26.13 $11,966 - $504,309
-19,300 Reduced 5.2%
352,133 $368,000
Q2 2022

Aug 12, 2022

BUY
$0.59 - $1.06 $20,709 - $37,206
35,100 Added 10.44%
371,433 $269,000
Q1 2022

May 13, 2022

SELL
$0.74 - $3.27 $5,920 - $26,160
-8,000 Reduced 2.32%
336,333 $336,000
Q4 2021

Feb 11, 2022

SELL
$2.02 - $2.9 $885,568 - $1.27 Million
-438,400 Reduced 56.01%
344,333 $820,000
Q3 2021

Nov 12, 2021

SELL
$1.95 - $2.85 $387,367 - $566,152
-198,650 Reduced 20.24%
782,733 $2.02 Million
Q2 2021

Aug 13, 2021

BUY
$2.7 - $5.04 $1.42 Million - $2.65 Million
526,041 Added 115.53%
981,383 $2.72 Million
Q1 2021

May 13, 2021

BUY
$4.38 - $7.0 $135,254 - $216,160
30,880 Added 7.28%
455,342 $2.27 Million
Q4 2020

Feb 10, 2021

BUY
$4.4 - $5.59 $911,768 - $1.16 Million
207,220 Added 95.39%
424,462 $1.91 Million
Q3 2020

Nov 13, 2020

BUY
$4.57 - $6.48 $100,997 - $143,208
22,100 Added 11.33%
217,242 $1.12 Million
Q2 2020

Aug 13, 2020

BUY
$4.87 - $7.37 $253,921 - $384,271
52,140 Added 36.46%
195,142 $1.06 Million
Q1 2020

May 14, 2020

BUY
$4.02 - $9.05 $233,192 - $524,972
58,008 Added 68.25%
143,002 $834,000
Q4 2019

Feb 13, 2020

BUY
$5.55 - $8.48 $339,765 - $519,137
61,219 Added 257.49%
84,994 $518,000
Q3 2019

Nov 13, 2019

BUY
$6.95 - $10.71 $165,236 - $254,630
23,775 New
23,775 $172,000

Others Institutions Holding NCNA

About NuCana plc


  • Ticker NCNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,196,000
  • Market Cap $112M
  • Description
  • NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...
More about NCNA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.